D
David Planchard
Researcher at Institut Gustave Roussy
Publications - 430
Citations - 28831
David Planchard is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 55, co-authored 352 publications receiving 19769 citations. Previous affiliations of David Planchard include Université Paris-Saclay & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
TL;DR: Standardized techniques and conditions for evaluating PD-L1 expression are critical for establishing the use of this protein as a predictive marker, and care should be also taken when using anti-PD-1/PD-L 1 therapies in combination with other therapies, which may impact the predictive value of PD- L1 expression.
Journal ArticleDOI
OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
Kazuhiko Nakagawa,Misako Nagasaka,Enriqueta Felip,Jose M. Pacheco,Christina S. Baik,Yasushi Goto,Andreas Saltos,Bob T. Li,Hibiki Udagawa,Shirish M. Gadgeel,Haruyasu Murakami,David Planchard,Lyudmilla Bazhenova,Luis Paz-Ares,Maurice Pérol,Julien Mazieres,Fabrice Barlesi,Kapil Saxena,Ryota Shiga,S. Acharyya,Y. Cheng,Javad Shahidi,Pasi A. Jänne,Egbert F. Smit +23 more
Journal ArticleDOI
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
Francesco Facchinetti,Ludovic Lacroix,Laura Mezquita,Jean-Yves Scoazec,Yohann Loriot,Lambros Tselikas,Anas Gazzah,Etienne Rouleau,Julien Adam,Stefan Michiels,Christophe Massard,Fabrice Andre,Ken A. Olaussen,Gilles Vassal,Karen Howarth,Benjamin Besse,Jean-Charles Soria,Luc Friboulet,David Planchard +18 more
TL;DR: Novel resistance mechanisms to BRAF/MEK inhibitors in BRAFV600E NSCLC were identified, pointing out the recurring involvement of the MAPK pathway and guiding the development of new treatment strategies.
Journal ArticleDOI
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
TL;DR: In this article, a review of the therapeutic strategies in non-small-cell lung cancer (NSCLC) with HER2 molecular alterations is presented, where the most encouraging data come from phase II studies that evaluated the antibody-drug conjugates (ADCs) ado-trastuzumab-emtansine and trastuzumaab-deruxtecan, with response rates of 50% and 62%, respectively.
Journal ArticleDOI
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
David Planchard,Harry J.M. Groen,Tae Min Kim,James R. Rigas,Pierre Jean Souquet,Christina S. Baik,Fabrice Barlesi,Julien Mazieres,Elisabeth Quoix,C. Martin Curtis,Bijoyesh Mookerjee,Arundathy N. Bartlett-Pandite,Christine Tucker,Anthony D'Amelio,Bruce E. Johnson +14 more
TL;DR: In this paper, the combination of D and T (DT) has demonstrated significant improvements in efficacy in terms of ORR in 78 BRAF V600E mut NSCLC pts, single agent D induced an overall response rate (ORR) of 32%.